Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer

Sep 23, 07:59 PM

Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.